作者
Micha Phill Grønholm Jepsen, Prajakta S Jogdand, Susheel K Singh, Meral Esen, Michael Christiansen, Saadou Issifou, Aurore B Hounkpatin, Ulysse Ateba-Ngoa, Peter G Kremsner, Morten H Dziegiel, Severin Olesen-Larsen, Søren Jepsen, Benjamin Mordmüller, Michael Theisen
发表日期
2013/8/1
期刊
The Journal of infectious diseases
卷号
208
期号
3
页码范围
479-488
出版商
Oxford University Press
简介
Background. GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.
Methods. Serum samples prior to vaccination and 4 weeks after the last vaccination from the 3 clinical trials were used to perform a comparative assessment of biological activity against Plasmodium falciparum.
Results. We showed that the maximum level of immunoglobulin G (IgG) antibodies obtained by GMZ2 vaccination is independent of ethnicity, time under malaria-exposure, and vaccine dose and that GMZ2 elicits high …
学术搜索中的文章
MPG Jepsen, PS Jogdand, SK Singh, M Esen… - The Journal of infectious diseases, 2013
